Aliya Pasik, PA
Psychiatric/Mental Health · Rochester Hills, MINPI 1578992632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,013 of the $15,150 with a category attached, or 72.7%. Tris Pharma Inc accounts for 78.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $7,030 and has fallen 85.7% since, to $1,009 in 2025. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $210.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$12K
- Supernus Pharmaceuticals, Inc.$1K
- Axsome Therapeutics, Inc.$355
- Takeda Pharmaceuticals U.S.A., Inc.$329
- Alkermes, Inc.$276
- Novo Nordisk$249
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$11,01373%
- Travel & lodging$8876%
- Food & beverage$3,24921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 21 | $11,875 |
| Supernus Pharmaceuticals, Inc. | 10 | $1,047 |
| Axsome Therapeutics, Inc. | 3 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $329 |
| Alkermes, Inc. | 8 | $276 |
| Novo Nordisk | 2 | $249 |
| Otsuka America Pharmaceutical, Inc. | 3 | $245 |
| Teva Pharmaceuticals USA, Inc. | 2 | $177 |
| Corium, LLC | 4 | $135 |
| Braeburn Inc. | 1 | $98 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Noven Therapeutics, LLC | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 1 | $46 |
| Johnson & Johnson | 2 | $44 |
| AbbVie | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Indivior Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quillivant$11,635
- Quillichew ER$11,635
- Dyanavel XR$11,635
- QELBREE$756
- Auvelity$355
- VYVANSE$313
- Ozempic$249
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- Azstarys$107
- REXULTI$107
- VIVITROL$107
How this compares
$15,150 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $41,895 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,094 |
| Atomoxetine Hcl | 65 | $6,070 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 97 | $5,009 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,748 |
| Bupropion XlBupropion Hcl | 150 | $4,485 |
| Methylphenidate ErMethylphenidate Hcl | 26 | $3,295 |
| Aripiprazole | 51 | $2,872 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 119 | $2,305 |
| Lamotrigine ErLamotrigine | 11 | $2,177 |
| Trazodone Hcl | 71 | $2,119 |
| Duloxetine Hcl | 59 | $1,914 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $1,655 |
| Naltrexone Hcl | 22 | $1,515 |
| Mirtazapine | 63 | $1,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $245 | $41,89514 claims |
| Alkermes, Inc.Lybalvi | $276 | $20,09413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $329 | $4,74812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Rochester Hills
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.